{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:47:09Z","timestamp":1785818829911,"version":"3.56.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiovascular diseases and metabolic disorders, including obesity and type 2 diabetes, remain leading global health challenges. Despite major advances in pharmacotherapy, the implementation of effective cardiometabolic prevention strategies remains suboptimal. Incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have substantially transformed the management of metabolic diseases by providing benefits beyond glycaemic control, including sustained weight loss, improvements in metabolic parameters, and cardiovascular risk reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate Polish healthcare professionals\u2019 perceptions of GLP-1 receptor agonists in cardiometabolic risk management, with particular emphasis on perceived effectiveness, safety, selected psychological and behavioural effects, and reimbursement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional online survey conducted among healthcare professionals in Poland between May and August 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A structured, anonymous online questionnaire was disseminated through professional, institutional, and academic communication channels in Poland. The questionnaire assessed self-reported perceptions, beliefs, perceived clinical value, perceived safety, and implementation-related views regarding GLP-1 receptor agonists in cardiometabolic risk management. The final analytical sample included 1,100 healthcare professionals representing physicians, nurses, pharmacists, dietitians, and physiotherapists. Categorical responses were compared between professional groups using the chi-square test or Fisher\u2019s exact test, as appropriate. Multivariable logistic regression was used to evaluate associations between respondent characteristics and selected perceptions; adjusted odds ratios (ORs) with 95% confidence intervals (CIs) and p-values were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The final analytical sample included 1,100 healthcare professionals: physicians (n = 164), pharmacists (n = 133), nurses (n = 160), physiotherapists (n = 361), and dietitians (n = 282). GLP-1 receptor agonists were most frequently rated as \u201cvery effective\u201d for weight loss by physiotherapists (87.3%) and dietitians (84.8%), followed by nurses (59.4%) and physicians (52.4%). Perceived safety was high across all groups, with GLP-1 receptor agonists considered safe by 94.0% of dietitians, 93.9% of physiotherapists, 87.2% of physicians, 85.0% of pharmacists, and 69.4% of nurses. Support for reimbursement was also high, ranging from 75.0% among nurses to 97.2% among dietitians. In multivariable analyses among physicians, employment in a diabetology or endocrinology setting was strongly associated with perceiving GLP-1 receptor agonists as very effective for weight reduction (adjusted OR 11.80, 95% CI 3.88\u201335.84; p &amp;lt; 0.001), as well as with perceived stress reduction (adjusted OR 2.71, 95% CI 1.05\u20137.02; p = 0.039), anxiety reduction (adjusted OR 7.00, 95% CI 2.01\u201324.42; p = 0.002), and improvement in depressive symptoms (adjusted OR 5.81, 95% CI 1.68\u201320.07; p = 0.005).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among participating healthcare professionals in Poland, GLP-1 receptor agonists were generally perceived as effective and safe options for cardiometabolic risk management. Perceptions differed across professional groups, particularly regarding weight reduction, safety, psychological and behavioural effects, and reimbursement. Because educational gaps, implementation barriers, real-world adoption, and interdisciplinary care models were not directly assessed as primary outcomes, these areas should be addressed in future studies using dedicated instruments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1906959","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:28:08Z","timestamp":1785817688000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Polish healthcare professionals\u2019 perceptions of GLP-1 receptor agonists in cardiometabolic risk reduction: a cross-sectional online survey in Poland"],"prefix":"10.3389","volume":"17","author":[{"given":"Weronika Faustyna","family":"Pucek","sequence":"first","affiliation":[{"name":"Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences","place":["Pozna\u0144, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Department and Clinic of Internal Diseases and Metabolic Disorders, Poznan University of Medical Sciences","place":["Pozna\u0144, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wies\u0142aw","family":"Bryl","sequence":"additional","affiliation":[{"name":"Department and Clinic of Internal Diseases and Metabolic Disorders, Poznan University of Medical Sciences","place":["Pozna\u0144, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Kus","sequence":"additional","affiliation":[{"name":"Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences","place":["Pozna\u0144, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Paczkowska","sequence":"additional","affiliation":[{"name":"Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences","place":["Pozna\u0144, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"B1","volume-title":"Global Health Estimates 2022: Deaths by Cause, Age, Sex, by Country and by Region, 2000\u20132022","year":"2023"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/biology11020288","article-title":"Gastrointestinal incretins-glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) beyond pleiotropic physiological effects are involved in pathophysiology of atherosclerosis and coronary artery disease-state of the art","volume":"11","author":"Jonik","year":"2022","journal-title":"Biol (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1210\/endrev\/bnaf006","article-title":"Glucose-dependent insulinotropic polypeptide in incretin physiology: Role in health and disease","volume":"46","author":"Wolfe","year":"2025","journal-title":"Endocr Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaf037","article-title":"Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis","volume":"11","author":"Kalayci","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s12933-025-02915-1","article-title":"Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes","volume":"24","author":"S\u00f8rensen","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12933-025-02874-7","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease","volume":"24","author":"Arow","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40842-025-00245-5","article-title":"From needles to pills: oral GLP-1 therapy enters the obesity arena","volume":"11","author":"Santulli","year":"2025","journal-title":"Cardiovasc Diabetol Endocrinol Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12933-025-02781-x","article-title":"Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of cardiovascular risk biomarkers in participants with type 2 diabetes or obesity without diabetes","volume":"24","author":"Wharton","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27031409","article-title":"Orforglipron: a comprehensive review of an oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes","volume":"27","author":"Kansakar","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40842-025-00270-4","article-title":"Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review","volume":"12","author":"Alper","year":"2026","journal-title":"Cardiovasc Diabetol Endocrinol Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1550938","article-title":"The effects of GLP-1 agonists on HbA1c and insulin dose among patients with type 1 diabetes","volume":"16","author":"Alhowiti","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02750-4","article-title":"The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications","volume":"24","author":"Duan","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.15310","article-title":"Multiomics insight into the role of glucagon-like peptide-1 receptor agonists in heart failure","volume":"12","author":"Tao","year":"2025","journal-title":"ESC Heart Fail"},{"key":"B20","doi-asserted-by":"publisher","first-page":"100632","DOI":"10.1016\/j.lanhl.2024.08.001","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug","volume":"5","author":"Mone","year":"2024","journal-title":"Lancet Healthy Longev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-026-00280-w","article-title":"Trends in the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists among ischemic stroke patients","volume":"12","author":"Ding","year":"2026","journal-title":"Clin Diabetes Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40842-026-00295-3","article-title":"The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis","volume":"12","author":"Peter","year":"2026","journal-title":"Cardiovasc Diabetol Endocrinol Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40842-026-00311-6","article-title":"Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals","volume":"12","author":"Ahuja","year":"2026","journal-title":"Cardiovasc Diabetol Endocrinol Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2016.1147025","article-title":"Physician perceptions of GLP-1 receptor agonists in the UK","volume":"32","author":"Matza","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/eurjcn\/zvab106","article-title":"Perceptions of injectable therapies with cardiovascular benefit: an ACNAP survey of healthcare professionals to explore facilitators and barriers","volume":"21","author":"Khatib","year":"2022","journal-title":"Eur J Cardiovasc Nurs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ahj.2020.03.017","article-title":"Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits","volume":"224","author":"Gao","year":"2020","journal-title":"Am Heart J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2337\/cd22-0100","article-title":"Health care provider prescribing habits and barriers to use of new type 2 diabetes medications: a single-system survey study","volume":"41","author":"Yaseen","year":"2023","journal-title":"Clin Diabetes"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.756","article-title":"Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists","volume":"10","author":"Garvey","year":"2024","journal-title":"Obes Sci Pract"},{"key":"B29","doi-asserted-by":"publisher","first-page":"18290","DOI":"10.1038\/s41598-024-69016-z","article-title":"Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors","volume":"14","author":"Liu","year":"2024","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12875-025-02837-7","article-title":"Barriers in prescribing antidiabetic medications with cardiovascular benefits: practice, experience, and attitudes of GPs in Croatia","volume":"26","author":"Kurevija","year":"2025","journal-title":"BMC Prim Care"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15620","article-title":"Effect of semaglutide 2.4\u2009mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials","volume":"26","author":"Rubino","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65521","article-title":"The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on the lipid profile of diabetic patients using statins: a retrospective cohort study in the diabetic center of King Salman Bin Abdulaziz Hospital, Saudi Arabia","volume":"16","author":"Albahli","year":"2024","journal-title":"Cureus"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2024.2363838","article-title":"Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"17","author":"Chae","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"S982","DOI":"10.1192\/j.eurpsy.2025.1993","article-title":"The impact of GLP-1 receptor agonists (GLP-1 RAs) on mental health: a systematic review","volume":"68","author":"Tempia Valenta","year":"2025","journal-title":"Eur Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/02813432.2025.2477141","article-title":"Patients' experiences with GLP1-RAs - a systematic review","volume":"43","author":"Ibsen","year":"2025","journal-title":"Scand J Prim Health Care"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077284","article-title":"The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice","volume":"8","author":"Egecioglu","year":"2013","journal-title":"PloS One"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0010-3","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats","volume":"43","author":"Hernandez","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2042018814558242","article-title":"Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus","volume":"6","author":"Harris","year":"2015","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.70661","article-title":"Efficacy and safety of glucagon-like peptide-1 agonists for psychiatric symptoms: a systematic review","volume":"15","author":"Meshkat","year":"2025","journal-title":"Brain Behav"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S531697","article-title":"Relative effectiveness and safety of the GLP-1 (glucagon-like peptide 1) receptor agonists, semaglutide and liraglutide in the treatment of obese type 2 diabetics: a prospective observational cohort study in Poland","volume":"18","author":"Hoffmann","year":"2025","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2586703","article-title":"The efficacy and safety of dual GIP\/GLP1 receptor agonists (tirzepatide) in diabetes and obesity: a systematic review and network meta-analysis","volume":"25","author":"Hoffmann","year":"2026","journal-title":"Expert Opin Drug Saf"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1906959\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:28:09Z","timestamp":1785817689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1906959\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":41,"alternative-id":["10.3389\/fendo.2026.1906959"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1906959","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"1906959"}}